Fujifilm Diosynth Biotechnologies, Merck To Invest $60 Million for Microbial Biologics Facility
Fujifilm Diosynth Biotechnologies, a contract biologics manufacturer, is in the process of establishing a long-term collaboration with MSD, the name for Merck & Co. outside the US and Canada, to invest in and operate a large-scale microbial biologics facility for the supply of active pharmaceutical ingredients (API) to its customers.
The collaboration involves a $60-million investment by MSD at its Brinny manufacturing plant in Innishannon, County Cork, Ireland. MSD in Brinny has been in operation for more than 30 years and is an integrated site for the development, testing, and manufacturing of biologics. It is intended that the large-scale biologics operations at MSD in Brinny will be operational in early 2018 for biotech and pharma customers of Fujifilm Diosynth.
Fujifilm Diosynth Biotechnologies currently operates manufacturing sites in Billingham, the UK and Research Triangle Park, North Carolina. The collaboration with Merc addresses a market need for large-scale microbial biologics manufacturing and complements the company’s existing microbial capacity that ranges from 100 L up to 5000 L both in the US and UK.